Xyvent-M Tablet is a combination medication containing Levocetirizine 5 mg and Montelukast 10 mg, formulated for the effective management of allergic conditions such as allergic rhinitis and chronic urticaria. Levocetirizine, a third-generation non-sedating antihistamine, selectively inhibits peripheral H1 receptors, thereby reducing symptoms like sneezing, nasal congestion, itching, and rhinorrhea. Montelukast, a leukotriene receptor antagonist, blocks the action of leukotrienes, inflammatory mediators involved in bronchoconstriction, mucus production, and airway edema, contributing to improved respiratory function and symptom relief. The synergistic effect of these active ingredients provides comprehensive control over allergic inflammation and bronchial hyperresponsiveness. Xyvent-M is indicated for patients requiring combined antihistaminic and anti-leukotriene therapy, particularly in cases where monotherapy is insufficient. It is generally well tolerated, with adverse effects including headache, fatigue, and gastrointestinal disturbances being infrequent and mild. Caution is advised in patients with hepatic impairment, and it should be used under medical supervision in pediatric and elderly populations. Xyvent-M Tablet offers a convenient once-daily dosing regimen, enhancing patient compliance in the long-term management of allergic disorders.